.
Join us for This Upcoming
Virtual Education Program
Dual Inhibition: Targeting Systemic and Localized Type 2 Inflammation in Asthma
Hosted by: Regeneron
Speaker: Wanda Phipatanakul, MD:
Wednesday, February 16th | 8:00 PM EDT
Use the link below to register and join this virtual event.
Hosted by: Regeneron
Speaker: Wanda Phipatanakul, MD:
Wednesday, February 16th | 8:00 PM EDT
Use the link below to register and join this virtual event.
A Bright Horizon: Staying Up To Date with New and
Emerging Therapies for Atopic Dermatitis
Hosted Jointly by: Potomac Center for Medical Education and Rockpointe.
This activity is supported through an educational grant from Pfizer Inc.
Accredited for ACCME/ABIM-ABAI-ABD MOC/MIPS
Tuesday, April 5, 2022 | 8:00 pm
Emerging Therapies for Atopic Dermatitis
Hosted Jointly by: Potomac Center for Medical Education and Rockpointe.
This activity is supported through an educational grant from Pfizer Inc.
Accredited for ACCME/ABIM-ABAI-ABD MOC/MIPS
Tuesday, April 5, 2022 | 8:00 pm
Program Overview:
Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment. This activity, “A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis”, aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence based use of newer targeted therapies, and how emerging therapies may impact AD management in
the near term.
Learning Objectives:
At the conclusion of this activity, participants should be able to:
Steering Committee:
Luz S. Fonacier, MD
Professor, Department of Medicine
NYU Long Island School of Medicine
Head of Allergy and Training Program Director in Allergy and Immunology
NYU Winthrop University Hospital
Mineola, NY
Andrew C. Krakowski, MD
Network Chair of Dermatology
Program Director for the Residency in Dermatology
St. Luke's University Health Network
Easton, PA
Shanthi Narla, MD
Dermatology Resident
St. Luke's University Health Network
Easton, PA
Accreditation statements:
Physician Credit Designation Statement
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
AMERICAN BOARD OF DERMATOLOGY (ABD) MOC INFORMATION
Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 CreditsTM annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.
MIPS CREDIT DESIGNATION STATEMENT
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment. This activity, “A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis”, aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence based use of newer targeted therapies, and how emerging therapies may impact AD management in
the near term.
Learning Objectives:
At the conclusion of this activity, participants should be able to:
- Discuss type 2 inflammatory processes and related physiologic pathways underlying atopic dermatitis pathophysiology.
- Identify patients with moderate to severe atopic dermatitis using evidence-based assessment tools
- Individualize atopic dermatitis action plans based on the goals and needs of the patient using a shared decision-making approach
- Evaluate the safety and efficacy of current and emerging targeted therapies for moderate to severe atopic dermatitis
Steering Committee:
Luz S. Fonacier, MD
Professor, Department of Medicine
NYU Long Island School of Medicine
Head of Allergy and Training Program Director in Allergy and Immunology
NYU Winthrop University Hospital
Mineola, NY
Andrew C. Krakowski, MD
Network Chair of Dermatology
Program Director for the Residency in Dermatology
St. Luke's University Health Network
Easton, PA
Shanthi Narla, MD
Dermatology Resident
St. Luke's University Health Network
Easton, PA
Accreditation statements:
Physician Credit Designation Statement
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
AMERICAN BOARD OF DERMATOLOGY (ABD) MOC INFORMATION
Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 CreditsTM annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.
MIPS CREDIT DESIGNATION STATEMENT
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Additional 2022 Virtual Programs
March - Hosted by Biocryst
May - Hosted by Regeneron
September - Hosted by Regeneron
November - Hosted by Regeneron
May - Hosted by Regeneron
September - Hosted by Regeneron
November - Hosted by Regeneron
Questions?
For other questions and more information, please contact the PAAA Meeting Manager, Lauren Newmaster at lnewmaster@pamedsoc.org
or (717) 909-2691.
For other questions and more information, please contact the PAAA Meeting Manager, Lauren Newmaster at lnewmaster@pamedsoc.org
or (717) 909-2691.
